Avid Bioservices Inc (CDMO)

[cjgaddy]

In June2019, MappBio got a BARDA contract for $16.5M, w/option for $30M more, for dev. of MBP091 to neutralize Marburg virus though the completion of a Phase 1 clinical trial.

6-11-19: “MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure”
…awarded an advanced R&D contract for $16.5M with options for an addl. $30M by BARDA… MBP091 is a single human monoclonal antibody (mAb) that is being developed as a pan-Marburg virus therapeutic for the treatment of hemorrhagic fevers caused by Marburg and the closely related Ravn virus. The mAb was isolated in the laboratory of Dr. James Crowe at Vanderbilt University Medical Center from a survivor or Marburg virus infection and subsequently licensed by Mapp. MBP091 has been evaluated in numerous preclinical experiments and has demonstrated the ability to neutralize Marburg virus in vitro and protect from lethal challenge of Marburg in vivo…
"We are pleased to continue and expand our productive relationship with BARDA, which represents a good example of a public-private partnership that advances much needed therapeutics for infected individuals and the Strategic National Stockpile," said Dr. Kevin J. Whaley, Mapp’s CEO.
About Mapp Biopharmaceutical:
Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. https://www.mappbio.com
This project has been funded in whole or in part with Federal funds from the Dept of HHS; Office of the Assistant Secretary for Preparedness and Response; BARDA, under Contract Nos. HHSO100201900018C and HHSO100201700023C, a NIH grant #2SB1 AI082744 and Medical CBRN Defense Consortium Base Agreement 2018-843 under OTA W15QKN-16-9-1002.

= = = = = =
8-26-20 Avid’s Known Customers Mkt-Caps
Pg.39 of 4-30-20 10-K (iss. 6-30-20):
1. Halozyme Therapeutics https://finance.yahoo.com/quote/HALO 3.9B
2. Gilead Sciences https://finance.yahoo.com/quote/GILD 82.7B
3. Acumen Pharmaceuticals PRIV: https://www.acumenpharm.com
4. IGM Biosciences https://finance.yahoo.com/quote/IGMS 1.5B
5. Coherus BioSciences https://finance.yahoo.com/quote/CHRS 1.4B
6. ADC Therapeutics America https://finance.yahoo.com/quote/ADCT 2.9B
NEW 8-2020:
7. Iovance Biotherapeutics https://finance.yahoo.com/quote/IOVA 4.2B
8. Oragenics https://finance.yahoo.com/quote/OGEN 58M
9. Mapp Biopharmaceutical (Private) https://mappbio.com BARDA #HHSO100201900018C

Aug2020 Adds:
8-6-20: IOVANCE Biotherapeutics signs w/Avid(+Aragen) to Dev+Mfg. IOV-3001 (IL-2 Analog) https://tinyurl.com/y2lgzh6x
BioProcIntl: “Iovance said it would focus on GMP manufacturing of IOV-3001 during 2020 and may initiate IND-enabling activities as early as 2021” https://tinyurl.com/y4ko9j7t
8-20-20: ORAGENICS Signs Dev/Mfg Agreement with Avid for COVID-19 Vaccine “TerraCoV2” https://tinyurl.com/yxqg3w4v
8-26-20: MAPP BIOPHARMACEUTICAL signs w/Avid for Clin. Dev. of Novel Antiviral Antibody https://tinyurl.com/yxwvr949 BARDA #HHSO100201900018C